Trial · NCT01674621
Adverse events135
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
81 to 100 of 135
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | Abaloparatide Transdermal (50 mcg) | 3 | 50 | |
| other | Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | Abaloparatide Transdermal (100 mcg) | 1 | 51 | |
| other | Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | Abaloparatide Transdermal (150 mcg) | 3 | 47 | |
| other | Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | Abaloparatide Injection (80 mcg) | 0 | 51 | |
| other | Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | Abaloparatide Transdermal Placebo (0 mcg) | 1 | 50 | |
| other | Injection site erythema | General disorders | Abaloparatide Transdermal (50 mcg) | 0 | 50 | |
| other | Injection site erythema | General disorders | Abaloparatide Transdermal (100 mcg) | 0 | 51 | |
| other | Injection site erythema | General disorders | Abaloparatide Transdermal (150 mcg) | 0 | 47 | |
| other | Injection site erythema | General disorders | Abaloparatide Injection (80 mcg) | 3 | 51 | |
| other | Injection site erythema | General disorders | Abaloparatide Transdermal Placebo (0 mcg) | 0 | 50 | |
| other | Upper respiratory tract infection | Infections and infestations | Abaloparatide Transdermal (50 mcg) | 0 | 50 | |
| other | Upper respiratory tract infection | Infections and infestations | Abaloparatide Transdermal (100 mcg) | 1 | 51 | |
| other | Upper respiratory tract infection | Infections and infestations | Abaloparatide Transdermal (150 mcg) | 0 | 47 | |
| other | Upper respiratory tract infection | Infections and infestations | Abaloparatide Injection (80 mcg) | 3 | 51 | |
| other | Upper respiratory tract infection | Infections and infestations | Abaloparatide Transdermal Placebo (0 mcg) | 1 | 50 | |
| serious | Coronary artery disease | Cardiac disorders | Abaloparatide Transdermal (50 mcg) | 0 | 50 | |
| serious | Coronary artery disease | Cardiac disorders | Abaloparatide Transdermal (100 mcg) | 0 | 51 | |
| serious | Coronary artery disease | Cardiac disorders | Abaloparatide Transdermal (150 mcg) | 0 | 47 | |
| serious | Coronary artery disease | Cardiac disorders | Abaloparatide Injection (80 mcg) | 1 | 51 | |
| serious | Coronary artery disease | Cardiac disorders | Abaloparatide Transdermal Placebo (0 mcg) | 0 | 50 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01674621/events?page=5